Presented at the Gastrointestinal Cancer Symposium; January 16–18, 2014; San Francisco, CA.
We conducted a phase I study to determine the maximum tolerated dose and recommended dose (RD) of this gemcitabine plus cisplatin (GC) combination in the adjuvant setting for biliary tract cancer (BTC). GC has become a standard chemotherapy regimen for patients with locally advanced or metastatic BTC; however, the benefit of adjuvant therapy for BTC is unclear.
Patients with BTC were eligible if they met the following criteria: Stage IB or higher; and undergoing resection without major hepatectomy. The starting dose matched the standard dose of gemcitabine (1,000 mg/m2) and cisplatin (25 mg/m2) on days 1 and 8, every 3 weeks for up to 24 weeks. The dose limiting toxicities (DLTs) were determined during the first 6 weeks, and a 3+3 dose finding design with cohorts of 3–6 patients was used. Further cohort expansion took place.
One DLT, namely grade 4 neutropenia, was observed among six patients at the starting dosages. Then, we expanded the cohort with a total of eighteen patients to evaluate RD and no further DLTs were observed. During the entire study, the most common grade 3/4 adverse events were neutropenia (94 %) and leucopenia (56 %). Non-hematological toxicities were manageable.
We defined the standard dose of GC as the RD for adjuvant chemotherapy for BTC treated by curative resection without major hepatectomy. Further study is warranted to clarify the safety and efficacy of this regimen for all patients.
Labour and Welfare Ministry of Health (2010) Handbook of health and welfare statistics. http://www.mhlw.go.jp/english/database/db-hh/
Howlader N, Noone AM, Krapcho M et al. SEER cancer static tics review, 1975–2008, National Cancer Institute. http://seer.cancer.gov/archive/csr/1975_2008/
Takada T, Amano H, Yasuda H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685–1695 PubMedCrossRef
Network NCC, NCCN clinical Practice Guidelines in Oncology; Hepatobiliary Cancers. Version 2. 2013
Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6(Suppl 6):7–13
Ho DH (1973) Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 33:2816–2820 PubMed
Venook AP, Egorin MJ, Rosner GL et al (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and Leukemia Group B 9565. J Clin Oncol 18:2780–2787 PubMed
Hall KS, Lien B, Endresen L, Bergan A, Rugstad HE (1991) Changes in pharmacokinetics of cisplatin after hepatic resection in rats. Drug Metab Dispos 19:725–728 PubMed
- Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II